Transgenomic, a provider of molecular technologies, has entered into a collaboration agreement to provide its next-generation genetic testing services, including the Nuclear Mitome test, to the Medical College of Wisconsin (MCW).
Under the agreement, MCW will use Nuclear Mitome test for mitochondrial disorders at its clinical sequencing programme to identify mutations in 448 genes that are considered important for mitochondrial function.
Mitochondrial disorders are caused by inherited or acquired mutations in mitochondrial DNA and can have an impact on the liver, the brain, kidneys and cardiovascular function, according to Transgenomic.
Craig Tuttle, Transgenomic chief executive officer, said by utilising next-generation sequencing technology, the Nuclear Mitome test is designed to improve the speed and precision of diagnosis for a host of mitochondrial disorders, allowing clinicians to plan the most effective treatment strategy.
"The Medical College of Wisconsin is a world-renowned institution with a robust presence in genomics and genetic testing," Tuttle added.
"This collaboration allows Transgenomic to rapidly expand the commercial use of our Nuclear Mitome Test in addition to building out our offerings in whole genome and exome testing. We look forward to working with MCW, and to building rapid value through these products."
Howard Jacob, Medical College of Wisconsin Human and Molecular Genetics Center director, said diagnosing mitochondrial disorders can be quite challenging and, until now, has typically involved the use of wide-ranging genetic and non-genetic tests, as well as consultation with various medical specialties.
"The ability to evaluate 400-plus genes with one diagnostic tool should shorten patients’ diagnostic odysseys and provide faster answers," Jacob added.